Study finds 20% of high-dose Brilinta patients quit on side effects; Novo touts cost-effectiveness analysis on GLP-1 med Victoza;

> A new analysis of Brilinta study data showed that about one in five heart attack patients on the highest dose of the AstraZeneca ($AZN) drug stopped taking it because of side effects. Report

> Novo Nordisk ($NVO) touted a company-funded study showing that Victoza, its GLP-1 diabetes drug, is more cost-effective than rival drugs from Sanofi ($SNY) and AstraZeneca ($AZN). Report

> The National Health Service in England published new guidance backing the use of AbbVie's ($ABBV) Humira in children with severe refractory uveitis, an inflammatory condition affecting the eye. Report

> Boehringer Ingelheim teamed up with a handful of top U.S. research institutions to develop new treatments for inflammatory bowel diseases such as Crohn's. Release

> And Finally... Allergan ($AGN), which makes Juvéderm facial fillers and other cosmetic treatments, released a survey showing that three-fourths of respondents worry that other people will misinterpret their "resting" facial expressions. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.